
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Cancer Therapy Precision
VERAXA Biotech announced in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-specific activation and reduced toxicity, positioning the company for partnership discussions at BIO 2026.
Read full story





















